EA200870336A1 - Полициклические производные циннамида - Google Patents

Полициклические производные циннамида

Info

Publication number
EA200870336A1
EA200870336A1 EA200870336A EA200870336A EA200870336A1 EA 200870336 A1 EA200870336 A1 EA 200870336A1 EA 200870336 A EA200870336 A EA 200870336A EA 200870336 A EA200870336 A EA 200870336A EA 200870336 A1 EA200870336 A1 EA 200870336A1
Authority
EA
Eurasian Patent Office
Prior art keywords
group
substituted
zinnamide
polycyclic derivatives
alkyl group
Prior art date
Application number
EA200870336A
Other languages
English (en)
Other versions
EA016464B1 (ru
Inventor
Тейдзи Кимура
Норитака Китазава
Тосихико Канеко
Нобуаки Сато
Коки Кавано
Коити Ито
Эрико Дои
Мамору Такаиси
Такео Сасаки
Такаси Доко
Такехико Миягава
Хироаки Хагивара
Original Assignee
Эйсай Ар Энд Ди Менеджмент Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эйсай Ар Энд Ди Менеджмент Ко., Лтд. filed Critical Эйсай Ар Энд Ди Менеджмент Ко., Лтд.
Publication of EA200870336A1 publication Critical patent/EA200870336A1/ru
Publication of EA016464B1 publication Critical patent/EA016464B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Abstract

Раскрыто соединение, представленное формулой (I), или его фармакологически приемлемая соль, где Arпредставляет собой имидазолильную группу, которая может быть замещена Салкильной группой или тому подобным, Arпредставляет собой фенильную группу, которая может быть замещена Салкоксигруппой или тому подобным, Xпредставляет собой двойную связь или тому подобное и Het представляет собой имидазолильную группу, которая может быть замещена Салкильной группой или тому подобным. Соединение или соль полезно(а) в качестве терапевтического или профилактического средства против заболевания, вызываемого Аβ.
EA200870336A 2006-03-09 2007-03-08 Полициклические производные арилимидазола EA016464B1 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US78051706P 2006-03-09 2006-03-09
JP2006063562 2006-03-09
US86170206P 2006-11-30 2006-11-30
JP2006322728 2006-11-30
PCT/JP2007/054532 WO2007102580A1 (ja) 2006-03-09 2007-03-08 多環式シンナミド誘導体

Publications (2)

Publication Number Publication Date
EA200870336A1 true EA200870336A1 (ru) 2009-02-27
EA016464B1 EA016464B1 (ru) 2012-05-30

Family

ID=38474999

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200870336A EA016464B1 (ru) 2006-03-09 2007-03-08 Полициклические производные арилимидазола

Country Status (16)

Country Link
EP (1) EP1992618B1 (ru)
KR (1) KR101464651B1 (ru)
AR (1) AR059955A1 (ru)
AU (1) AU2007223158B2 (ru)
CA (1) CA2643796A1 (ru)
CY (1) CY1112767T1 (ru)
EA (1) EA016464B1 (ru)
GE (1) GEP20115139B (ru)
HK (2) HK1122027A1 (ru)
HN (1) HN2008001374A (ru)
HR (1) HRP20120174T1 (ru)
IL (1) IL193770A (ru)
MA (1) MA30268B1 (ru)
MX (1) MX2008011221A (ru)
PL (1) PL1992618T3 (ru)
WO (1) WO2007102580A1 (ru)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY149038A (en) 2004-05-26 2013-07-15 Eisai R&D Man Co Ltd Cinnamide compound
KR20070083781A (ko) 2004-10-26 2007-08-24 에자이 알앤드디 매니지먼트 가부시키가이샤 신나미드 화합물의 비정질체
BRPI0618814A2 (pt) 2005-11-24 2014-04-29 Eisai R&D Man Co Ltd Composto ou um sal farmacologicamente aceitável do mesmo, e, agente farmacêutico
TWI370130B (en) 2005-11-24 2012-08-11 Eisai R&D Man Co Ltd Two cyclic cinnamide compound
TWI378091B (en) 2006-03-09 2012-12-01 Eisai R&D Man Co Ltd Multi-cyclic cinnamide derivatives
AR062095A1 (es) 2006-07-28 2008-10-15 Eisai R&D Man Co Ltd Profarmaco de compuesto cinamida
CA2677296A1 (en) * 2007-02-08 2008-08-14 Merck & Co., Inc. Therapeutic agents
US20080207900A1 (en) 2007-02-28 2008-08-28 Teiji Kimura Two cyclic oxomorphorin derivatives
WO2008138753A1 (en) 2007-05-11 2008-11-20 F. Hoffmann-La Roche Ag Hetarylanilines as modulators for amyloid beta
AU2008263207B2 (en) * 2007-06-01 2013-10-03 Merck Sharp & Dohme Corp. Gamma secretase modulators
CL2008002542A1 (es) * 2007-08-31 2009-01-02 Eisai R&D Man Co Ltd Compuestos derivados de imidazolil piridina ligados a un heterociclo mediante un vinilo, moduladores de la actividad de amiloide-beta; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de enfermedades tales como alzheimer, demencia, sindrome de down o amiloidosis.
US7935815B2 (en) * 2007-08-31 2011-05-03 Eisai R&D Management Co., Ltd. Imidazoyl pyridine compounds and salts thereof
MX2010005028A (es) 2007-11-05 2010-05-27 Schering Corp Moduladores de gamma secretasa.
MX2010006379A (es) * 2007-12-11 2010-09-07 Schering Corp Moduladores de la secretasa gamma.
KR20100135711A (ko) 2007-12-20 2010-12-27 엔비보 파마슈티칼즈, 인코퍼레이티드 사중치환된 벤젠
KR101204213B1 (ko) 2007-12-21 2012-11-26 에프. 호프만-라 로슈 아게 오렉신 수용체 길항제로서의 헤테로아릴 유도체
CN101910142B (zh) 2008-01-11 2013-07-10 弗·哈夫曼-拉罗切有限公司 β-淀粉状蛋白的调节剂
AU2009216851B2 (en) 2008-02-22 2013-11-07 F. Hoffmann-La Roche Ag Modulators for amyloid beta
RU2011111534A (ru) * 2008-08-27 2012-10-10 ЭЙСАЙ Ар энд Ди МЕНЕДЖМЕНТ КО., ЛТД. (JP) Способ получения определенных цинниамидных соединений
CA2736924C (en) 2008-10-09 2016-06-28 F. Hoffmann-La Roche Ag Modulators for amyloid beta
WO2010054064A1 (en) * 2008-11-06 2010-05-14 Schering Corporation Gamma secretase modulators
US20120129846A1 (en) * 2008-11-06 2012-05-24 Zhaoning Zhu Gamma secretase modulators
CN102209537A (zh) 2008-11-10 2011-10-05 弗·哈夫曼-拉罗切有限公司 杂环γ分泌酶调节剂
JP2012508748A (ja) 2008-11-13 2012-04-12 シェーリング コーポレイション γ−セクレターゼ調節剤
AR074701A1 (es) * 2008-12-22 2011-02-02 Schering Corp Moduladores de gamma secretasa
TW201030002A (en) * 2009-01-16 2010-08-16 Bristol Myers Squibb Co Bicyclic compounds for the reduction of beta-amyloid production
JP2012051807A (ja) * 2009-02-26 2012-03-15 Eisai R & D Management Co Ltd アリールイミダゾール化合物
JP2012051805A (ja) 2009-02-26 2012-03-15 Eisai R & D Management Co Ltd テトラヒドロトリアゾロピリジン誘導体の製造方法
BRPI1007883A2 (pt) 2009-02-26 2016-02-23 Eisai R&D Man Co Ltd sal, e, cristal.
JP2012121809A (ja) * 2009-02-26 2012-06-28 Eisai R & D Management Co Ltd 多環式化合物の製造法およびその中間体
TW201035101A (en) * 2009-02-26 2010-10-01 Eisai R&D Man Co Ltd Nitrogen-containing fused heterocyclic compound
CN102482276A (zh) 2009-07-13 2012-05-30 武田药品工业株式会社 杂环化合物及其用途
US8871760B2 (en) * 2009-09-21 2014-10-28 Roche Palo Alto Llc [1,2,4]triazolo[3,4-C][1,4]oxazines as P2X7 modulators
KR20120123677A (ko) * 2010-01-15 2012-11-09 얀센 파마슈티칼즈, 인코포레이티드 감마 세크레타제 조절제로서의 신규 치환된 비사이클릭 트리아졸 유도체
US8486967B2 (en) 2010-02-17 2013-07-16 Hoffmann-La Roche Inc. Heteroaryl substituted piperidines
CA2791914C (en) 2010-03-05 2019-01-15 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
SG187917A1 (en) * 2010-09-02 2013-04-30 Takeda Pharmaceutical Fused triazoles for the treatment or prophylaxis of mild cognitive impairment
JP2014012641A (ja) * 2010-10-29 2014-01-23 Dainippon Sumitomo Pharma Co Ltd 新規ピリジン誘導体
US9303000B2 (en) * 2011-01-17 2016-04-05 Karyopharm Therapeutics Inc. Olefin containing nuclear transport modulators and uses thereof
PT2736887T (pt) 2011-07-29 2018-01-15 Karyopharm Therapeutics Inc Modeladores de transporte nuclear contendo hidrazida e utilizações dos mesmos
WO2013019561A1 (en) 2011-07-29 2013-02-07 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
US9708276B2 (en) 2011-10-12 2017-07-18 University of Pittsburgh—of the Commonwealth System of Higher Education Small molecules targeting androgen receptor nuclear localization and/or level in prostate cancer
KR20200115688A (ko) 2012-05-09 2020-10-07 바이오젠 엠에이 인코포레이티드 핵 수송 조절인자 및 이의 용도
KR102096625B1 (ko) 2012-05-16 2020-04-03 얀센 파마슈티칼즈, 인코포레이티드 (무엇보다도) 알츠하이머병의 치료에 유용한 치환 3,4-디하이드로-2h-피리도[1,2-a]피라진-1,6-디온 유도체
EP2687528A1 (en) * 2012-07-17 2014-01-22 Ares Trading S.A. Fused triazole derivatives as gamma secretase modulators
EP2953949B1 (en) 2012-12-20 2016-09-28 Janssen Pharmaceutica NV Novel tricyclic 3,4-dihydro-2h-pyrido[1,2-a]pyrazine-1,6-dione derivatives as gamma secretase modulators
AU2014206834B2 (en) 2013-01-17 2017-06-22 Janssen Pharmaceutica Nv Novel substituted pyrido-piperazinone derivatives as gamma secretase modulators
EP2968278B8 (en) 2013-03-15 2019-05-22 Karyopharm Therapeutics Inc. Methods of promoting wound healing using crm1 inhibitors
ME03421B (me) 2013-06-21 2020-01-20 Karyopharm Therapeutics Inc 1,2,4-triazoli kao modulatori nuklearnog transporta i njihova upotreba
WO2015042297A1 (en) 2013-09-20 2015-03-26 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Compounds for treating prostate can cancer
US20160257657A1 (en) 2013-09-20 2016-09-08 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer
US10562897B2 (en) 2014-01-16 2020-02-18 Janssen Pharmaceutica Nv Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators
EA201790384A1 (ru) 2014-08-15 2017-08-31 Кариофарм Терапевтикс, Инк. Полиморфы селинексора
US10709706B2 (en) 2015-12-31 2020-07-14 Karopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
WO2017117529A1 (en) 2015-12-31 2017-07-06 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
US10980806B2 (en) 2016-03-24 2021-04-20 University of Pittsburgh—of the Commonwealth System of Higher Education Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer
US11602530B2 (en) 2016-11-28 2023-03-14 Biogen Ma Inc. CRM1 inhibitors for treating epilepsy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2956702A (en) * 2000-12-04 2002-06-18 Hoffmann La Roche Phenylethenyl or phenylethinyl derivatives as glutamate receptor antagonists
CA2514363A1 (en) * 2003-02-12 2004-08-26 Transtech Pharma, Inc. Substituted azole derivatives as therapeutic agents
JP4898458B2 (ja) * 2004-02-12 2012-03-14 トランス テック ファーマ，インコーポレイテッド 置換アゾール誘導体、組成物及び使用方法
MY149038A (en) * 2004-05-26 2013-07-15 Eisai R&D Man Co Ltd Cinnamide compound

Also Published As

Publication number Publication date
AU2007223158A1 (en) 2007-09-13
EP1992618B1 (en) 2012-01-18
EA016464B1 (ru) 2012-05-30
EP1992618A1 (en) 2008-11-19
CA2643796A1 (en) 2007-09-13
AR059955A1 (es) 2008-05-14
KR101464651B1 (ko) 2014-11-24
HK1122027A1 (en) 2009-05-08
IL193770A (en) 2012-10-31
MX2008011221A (es) 2008-09-11
PL1992618T3 (pl) 2012-06-29
HRP20120174T1 (hr) 2012-03-31
HK1128085A1 (en) 2009-10-16
HN2008001374A (es) 2011-03-15
AU2007223158B2 (en) 2012-04-12
WO2007102580A1 (ja) 2007-09-13
CY1112767T1 (el) 2016-02-10
MA30268B1 (fr) 2009-03-02
GEP20115139B (en) 2011-01-10
EP1992618A4 (en) 2010-11-10
IL193770A0 (en) 2009-05-04
KR20080108481A (ko) 2008-12-15

Similar Documents

Publication Publication Date Title
EA200870336A1 (ru) Полициклические производные циннамида
ATE541836T1 (de) Polycyclische cinnamid-derivate
MY150507A (en) Polycyclic compound
ME01992B (me) Jedinjenje diarilhidantoina
RS52823B (en) NEW UNITS USEFUL FOR TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES
WO2010105179A3 (en) Inhibitors of beta-secretase
RS52716B (en) HYDROBENZAMIDE DERIVATIVES AS HEAT SHOCK PROTEIN INHIBITORS HSP90
MA35452B1 (fr) 3-pyrimidin-4-yl-oxazolidin-2-ones comme inhibiteurs d'idh mutante
MX2011008501A (es) Compuestos heterociclicos fusionados que contienen nitrogeno y su uso como inhibidores de la produccion de beta-amiloide.
MX2009009492A (es) Compuestos organicos biciclicos adecuados para el tratamiento de condiciones inflamatorias o alergicas.
EA200801160A1 (ru) Алкоксиалкилзамещённые спироциклические тетрамовые и тетроновые кислоты
RS53142B (en) UNITS THAT HAVE ANTAGONISTIC ACTIVITY ON CRTH2
EA201170176A1 (ru) Ингибитор stat3, содержащий хинолинкарбоксамидное производное в качестве активного ингредиента
EA200801381A1 (ru) Производные пиримидина
TW200612958A (en) Substituted imidazole derivatives
WO2008108386A1 (ja) 医薬組成物
ATE542798T1 (de) Organische verbindungen
RS53617B1 (en) NEW UNITS USEFUL FOR TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES
RS53003B (en) C7-FLUORO SUBSTITUTED TETRACYCLINE UNITS
EA200900924A1 (ru) Циклизованные производные как ингибиторы eg-5
EA201000104A1 (ru) Производные пиримидина, применимые для лечения воспалительных или аллергических патологических состояний
EA200801596A1 (ru) Новые 11-бета-гидроксиандроста-4-ен-3-оны
EA200801366A1 (ru) Производные 3,6-дигидро-2-оксо-6н-1,3,4-тиадиазина
DE602007011434D1 (de) 1h-indol-5-ylpiperazin-1-ylmethanonderivate
WO2008136378A1 (ja) 新規なスルホンアミド誘導体またはその塩

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU